Budget impact analysis of cabergoline for medical treatment of Cushing’s disease in Brazil

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorUniversidade Estadual Paulista (UNESP)-
Autor(es): dc.contributorFaculty of Medicine and University Hospital of Cologne-
Autor(es): dc.contributorUniversidade Federal do Ceará-
Autor(es): dc.creatorSilva, Lukas Fernando de Oliveira-
Autor(es): dc.creatorGalendi, Julia Simões Corrêa-
Autor(es): dc.creatorMartins, Manoel Ricardo Alves-
Autor(es): dc.creatorNogueira, Vania Dos Santos Nunes-
Data de aceite: dc.date.accessioned2025-08-21T20:19:41Z-
Data de disponibilização: dc.date.available2025-08-21T20:19:41Z-
Data de envio: dc.date.issued2025-04-29-
Data de envio: dc.date.issued2023-12-31-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.20945/2359-4292-2023-0311-
Fonte completa do material: dc.identifierhttps://hdl.handle.net/11449/300091-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/300091-
Descrição: dc.descriptionObjective: The aim of this study was to estimate the budget impact of adding cabergoline to the Brazilian Unified Health System (SUS) formulary for the treatment of patients with Cushing’s disease (CD) who do not achieve disease control after transsphenoidal surgery. Materials and methods: We conducted a budget impact analysis (BIA) from the perspective of the Brazilian SUS over a 5-year time horizon. We compared two scenarios: ketoconazole (Scenario 1) versus including cabergoline as a treatment option (Scenario 2). All analyses were conducted using Microsoft Excel. Uncertainty was explored in univariate sensitivity analyses. Results: The total costs were BRL $25,596,729 for Scenario 1 and BRL $32,469,169 for Scenario 2. The budget impact of adding cabergoline to the formulary for CD treatment within the SUS would be BRL $6,091,036 over 5 years. On univariate analyses, variations in the rates of surgical failure and CD recurrence had the greatest potential to affect the final costs associated with cabergoline. Conclusions: The estimated budget impact of adding cabergoline to the formulary for CD treatment within the Brazilian SUS would be about BRL $6 million. While cost savings cannot be expected, the budget impact of adding cabergoline would be lower than that of adding other treatment options for CD.-
Descrição: dc.descriptionFaculdade de Medicina de Botucatu Universidade Estadual Paulista, SP-
Descrição: dc.descriptionInstitute of Health Economics and Clinical Epidemiology Faculty of Medicine and University Hospital of Cologne-
Descrição: dc.descriptionDepartamento de Medicina Clínica e Núcleo de Pesquisa e Desenvolvimento de Medicamentos Faculdade de Medicina Universidade Federal do Ceará, CE-
Descrição: dc.descriptionFaculdade de Medicina de Botucatu Universidade Estadual Paulista, SP-
Idioma: dc.languageen-
Relação: dc.relationArchives of Endocrinology and Metabolism-
???dc.source???: dc.sourceScopus-
Palavras-chave: dc.subjectACTH-secreting pituitary adenoma-
Palavras-chave: dc.subjectbudget impact analysis-
Palavras-chave: dc.subjectCushing syndrome-
Palavras-chave: dc.subjecthealth care costs-
Título: dc.titleBudget impact analysis of cabergoline for medical treatment of Cushing’s disease in Brazil-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.